Agilent Technologies (NYSE:A) Upgraded at Barclays

Agilent Technologies (NYSE:A) was upgraded by stock analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research report issued to clients and investors on Monday, Marketbeat reports. The brokerage currently has a $165.00 price objective on the medical research company’s stock. Barclays‘s target price would indicate a potential upside of 16.66% from the stock’s current price.

A number of other equities analysts also recently issued reports on the stock. TD Cowen increased their price target on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. The Goldman Sachs Group initiated coverage on shares of Agilent Technologies in a report on Tuesday, December 9th. They issued a “buy” rating and a $170.00 target price for the company. UBS Group boosted their price target on Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Rothschild & Co Redburn started coverage on Agilent Technologies in a research note on Wednesday, October 8th. They issued a “buy” rating and a $165.00 price objective for the company. Finally, Rothschild Redb raised shares of Agilent Technologies to a “strong-buy” rating in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $161.77.

Agilent Technologies Stock Performance

NYSE A opened at $141.44 on Monday. The business’s 50-day moving average price is $145.59 and its 200 day moving average price is $129.27. The company has a quick ratio of 1.52, a current ratio of 1.96 and a debt-to-equity ratio of 0.45. The firm has a market cap of $40.10 billion, a P/E ratio of 30.83, a P/E/G ratio of 4.05 and a beta of 1.27. Agilent Technologies has a 52-week low of $96.43 and a 52-week high of $160.27.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.01. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.The company had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same period last year, the business posted $1.46 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. On average, equities research analysts expect that Agilent Technologies will post 5.58 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 12,490 shares of Agilent Technologies stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the transaction, the chief executive officer owned 33,448 shares in the company, valued at approximately $5,017,200. The trade was a 27.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Rodney Gonsalves sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $154.99, for a total transaction of $464,970.00. Following the sale, the vice president directly owned 31,846 shares of the company’s stock, valued at approximately $4,935,811.54. This trade represents a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 16,401 shares of company stock worth $2,468,962.

Institutional Trading of Agilent Technologies

Hedge funds have recently made changes to their positions in the company. Capital A Wealth Management LLC increased its stake in Agilent Technologies by 10,600.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company’s stock worth $25,000 after buying an additional 212 shares during the period. Davis Capital Management acquired a new stake in shares of Agilent Technologies during the third quarter valued at about $28,000. Physician Wealth Advisors Inc. increased its position in shares of Agilent Technologies by 490.0% during the third quarter. Physician Wealth Advisors Inc. now owns 236 shares of the medical research company’s stock worth $30,000 after acquiring an additional 196 shares during the last quarter. Ransom Advisory Ltd acquired a new position in shares of Agilent Technologies in the first quarter worth about $32,000. Finally, Central Pacific Bank Trust Division purchased a new position in Agilent Technologies in the second quarter valued at about $33,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.